高级搜索

MVP方案治疗非小细胞肺癌的疗效观察

熊建萍, 万以叶, 王迪进, 陈文俊

熊建萍, 万以叶, 王迪进, 陈文俊. MVP方案治疗非小细胞肺癌的疗效观察[J]. 肿瘤防治研究, 1999, 26(4): 295-296.
引用本文: 熊建萍, 万以叶, 王迪进, 陈文俊. MVP方案治疗非小细胞肺癌的疗效观察[J]. 肿瘤防治研究, 1999, 26(4): 295-296.
XIONG Jing-ping, WAN Yi-ye, WANG Di-jin, CHEN Wen-jun. Mitomycin plus Vindesine and Cispltin in patients with Non-small cell lung cancer[J]. Cancer Research on Prevention and Treatment, 1999, 26(4): 295-296.
Citation: XIONG Jing-ping, WAN Yi-ye, WANG Di-jin, CHEN Wen-jun. Mitomycin plus Vindesine and Cispltin in patients with Non-small cell lung cancer[J]. Cancer Research on Prevention and Treatment, 1999, 26(4): 295-296.

MVP方案治疗非小细胞肺癌的疗效观察

Mitomycin plus Vindesine and Cispltin in patients with Non-small cell lung cancer

  • 摘要: 目的: 观察MVP方案治疗非小细胞肺癌(NSCLC)的治疗效果和毒性反应。方法: 45例非小细胞肺癌患者使用MVP(MMC +VDS +DDP) 方案治疗。结果: 45例患者中21例有效, 有效率为46.7 %。分析诸因素对疗效的影响发现病期早较病期晚疗效好。生活质量评估Karnofsky评分升高为68.9 %。骨髓抑制为剂量限制性毒性, 白细胞下降75.6 %无其他严重毒副反应发生。结论: MVP方案是治疗非小细胞肺癌有效且可以耐受的方案。
    Abstract: Objective: Observe the therapeutic effects and toxicity reaction of MVP regimen for the treatment of non-small cell lung cancer (NSCLC). Methods: 45 cases were treated with MVP (MMC +VDS +DDP) regimen. Results: Response rates were 46.7 % (21/45). Neutropeniawas the dose-limited toxicity and was occurred in 75.6 % of cases. No other serious side reaction occurred in all patients. Conclusions: There was definitive good therapeutic effect but slight side reaction with MVP regimen in the treatment of NSCLC.
  • [1] 廖美琳.非小细胞肺癌(NSCLC)临床治疗进展.实用肿瘤杂志, 1997, 12(6): 241;
    [2] Karwahra M, Furuse Kodama N, etal. A randomized study of cisplatin vesus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer, 1991, 68: 714.
计量
  • 文章访问数:  1760
  • HTML全文浏览量:  93
  • PDF下载量:  551
  • 被引次数: 0
出版历程
  • 刊出日期:  1999-08-04

目录

    CHEN Wen-jun

    1. On this Site
    2. On Google Scholar
    3. On PubMed

    /

    返回文章
    返回
    x 关闭 永久关闭